Sector pending / Pharmaceutical PreparationsUpdated 2026-05-10 22:07 UTC

FRA/8RP stock hub

FRA/8RP has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/8RPis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

271.1M

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/8RPFRA/8RP

—

Loading chart…

In the news

Latest news · FRA/8RP

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-27

P25 n/aP50 n/aP75 n/a

ROIC-29.9

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/8RP market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

175

Groups with data

Currency

PLN

Showing 175 of 175 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Poland
Country code	DE
Employees	566
Employees Change	4%
Employees Change Percent	0.71
Enterprise value	EUR 269.5M
Exchange	Frankfurt Stock Exchange
Financial currency	PLN
First seen	2026-05-10
Industry	Pharmaceutical Preparations
Last refreshed	2026-05-10
Market cap	EUR 271.1M
Price	EUR 4.86
Price currency	EUR
Rev Per Employee	93,410.09x
Sic	2834
Symbol	fra/8RP
Website	https://www.celonpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-10.58%
EV Earnings	-9.39x
EV/FCF	-27.89x
EV/Sales	5.05x
FCF yield	-3.56%
P/B ratio	2.97x
P/S ratio	5.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-49.63%
EBITDA Margin	-38.14%
Gross margin	68.32%
Gross Profit	EUR 36.1M
Gross Profit Growth	5.44%
Gross Profit Growth Q	63.25%
Gross Profit Growth3 Y	7.59%
Gross Profit Growth5 Y	9.16%
Net Income	EUR -28.7M
Net Income Growth Q	-93.59%
Pretax Margin	-56.05%
Profit Margin	-54.25%
Profit Per Employee	EUR -50,677
ROA	-12.84
Roa5y	-2.78
ROCE	-26.86
ROE	-27.03
Roe5y	-4.85
ROIC	-29.93
Roic5y	-7.56

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-9.84%
Cagr3y	17.29%
Cagr5y	-12.92%
Div CAGR3	-2.62%
Div CAGR5	3.93%
EPS Growth Q	-93.4
OCF Growth10 Y	-28.13%
OCF Growth5 Y	-58.09%
Revenue Growth	7.29x
Revenue Growth Q	39.34x
Revenue Growth3 Y	5.64x
Revenue Growth5 Y	9.68x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.41
Assets	EUR 110.5M
Cash	EUR 4.9M
Current Assets	EUR 24.3M
Current Liabilities	EUR 12.8M
Debt	EUR 3.3M
Debt Equity	EUR 0.04
Debt FCF	EUR -0.34
Equity	EUR 91.2M
Interest Coverage	-58.14
Liabilities	EUR 19.3M
Long Term Assets	EUR 86.1M
Long Term Liabilities	EUR 6.4M
Net Cash	EUR 1.6M
Net Cash By Market Cap	EUR 0.59
Net Cash Growth	-92.31%
Net Debt Equity	EUR -0.02
Tangible Book Value	EUR 90.6M
Tangible Book Value Per Share	EUR 1.68

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.9
Inventory Turnover	2.82
Net Working Capital	EUR 8.3M
Quick ratio	1.38
Working Capital	EUR 11.4M
Working Capital Turnover	EUR 0.62

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	1.95%
Dividend per share	EUR 0
Last Dividend	EUR 0.02

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-9.83%
200-day SMA	4.94
3Y total return	61.37%
50-day SMA	4.83
50-day SMA vs 200-day SMA	50under200
5Y total return	-49.93%
All Time High	11.4
All Time High Change	-57.37%
All Time High Date	2021-04-19
All Time Low	2.49
All Time Low Change	95.57%
All Time Low Date	2022-10-14
ATR	0.26
Ch YTD	8.24
High	4.86
High52	5.77
High52 Date	2026-02-16
High52ch	-15.77%
Low	4.86
Low52	4.27
Low52 Date	2025-12-29
Low52ch	13.95%
Ma50ch	0.54%
Price vs 200-day SMA	-1.54%
RSI	50.11
RSI Monthly	47.66
RSI Weekly	49.34
Sharpe ratio	0.12x
Sortino ratio	0.28
Total Return	1.95%
Tr YTD	8.24
Tr1m	7.4%
Tr1w	1.99%
Tr3m	-6%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR -26.2M
Operating Income Growth Q	-85.77
Operating margin	-49.63

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	23,828,969%
Net Borrowing	-2,435,787.3
Shares Institutions	10.36%
Shares Qo Q	-2.57%
Shares Yo Y	-1.95%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR -9.1M
Average Volume	5.35x
Bv Per Share	1.69
CAPEX	EUR -9.8M
Ch1m	7.4
Ch1w	1.99
Ch1y	-9.83
Ch3m	-6
Ch3y	59.61
Ch5y	-51.5
Change	-8.82%
Change From Open	0
Close	5.33
Days Gap	-8.82
Depreciation Amortization	6,114,467.7
Earnings Date	2026-04-22
EBIT	EUR -26.2M
EBITDA	EUR -20.2M
EPS	EUR -0.55
F Score	3
FCF	EUR -9.7M
FCF EV Yield	-3.59x
Financing CF	-3,771,699
Fiscal Year End	December
Founded	2,002
Income Tax	EUR -950,307
Investing CF	2,645,158
Is Primary Listing	0
Last Earnings Date	2026-04-22
Last Report Date	2025-09-30
Ma150	4.87
Ma150ch	-0.18%
Ma20	4.87
Ma20ch	-0.18%
Net CF	-1,015,926
Next Earnings Date	2026-05-20
Open	4.86
P OCF Ratio	2,445.4
Ppne	69,492,578.4
Price Date	2026-05-08
Ptbv Ratio	2.99
Relative Volume	0.19x
Revenue	52,870,113x
SBC By Revenue	-1.01x
Share Based Comp	-533,156
Tax By Revenue	-1.8x
Volume	0
Z Score	9.12

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/8RP pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/8RP stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/8RP?

Insider, institutional, and short-interest positioning.

Institutional ownership

+10.4%

Share of float held by funds and institutions

Insider ownership

n/a

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-2.0%

Negative means the company is buying back shares.

Technical

FRA/8RP momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

50.1

Neutral momentum band

Price vs 200-day MA

-1.5%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.12

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/8RP

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/8RP stock rating?

fra/8RP is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/8RP analysis?

The full report lives at /stocks/fra/8RP/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/8RP?

The latest report frames fra/8RP around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/8RP page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.